XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 27 2025
0mins
Should l Buy XOMA?
Source: Newsfilter
XOMA Royalty Acquires Royalty Interests: XOMA Royalty Corporation has purchased future royalty and milestone interests in mezagitamab from BioInvent International for $20 million, with a potential total transaction value of up to $30 million, enhancing its late-stage royalty portfolio.
BioInvent's Strategic Partnership: The deal provides BioInvent with non-dilutive capital to advance its clinical drug development programs while highlighting the value of its n-CoDeR® platform in identifying promising therapeutic antibody candidates.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XOMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XOMA
Wall Street analysts forecast XOMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XOMA is 71.00 USD with a low forecast of 50.00 USD and a high forecast of 97.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 24.920
Low
50.00
Averages
71.00
High
97.00
Current: 24.920
Low
50.00
Averages
71.00
High
97.00
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
XOMA Corporation Under Investigation, Stock Plummets 22.76%
- Investigation Launched: Pomerantz LLP is investigating whether XOMA Royalty Corporation has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock declines.
- Poor Clinical Trial Results: The Phase 3 sunRIZE study results released by Rezolute, Inc. indicate that ersodetug failed to meet its primary endpoint in treating congenital hyperinsulinism, raising concerns about XOMA's future prospects in the market.
- Significant Stock Drop: Following the unfavorable news, XOMA's stock price fell by $7.82, or 22.76%, closing at $25.39 per share on December 19, 2025, reflecting investor disappointment in the company's outlook.
- Increased Legal Risks: As the investigation progresses, XOMA may face heightened legal liabilities and potential compensation claims, which could have long-term negative impacts on the company's financial health and market reputation.
See More
XOMA Corporation Under Investigation, Stock Plummets 22.76%
- Investigation Launched: Pomerantz LLP is investigating whether XOMA Royalty Corporation has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock volatility.
- Disappointing Clinical Trial Results: Rezolute, Inc.'s Phase 3 sunRIZE study results indicate that ersodetug failed to meet its primary endpoint in treating congenital hyperinsulinism, potentially impacting XOMA's market outlook.
- Significant Stock Drop: Following the adverse news, XOMA's stock price fell by $7.82, or 22.76%, closing at $25.39 on December 19, 2025, reflecting market pessimism regarding the company's future.
- Increased Legal Risks: As the investigation unfolds, XOMA faces potential legal liabilities and compensation risks, which could adversely affect its financial condition and investor trust in the long term.
See More
XOMA Royalty CFO Thomas Burns Resigns, Jeffrey Trigilio Appointed
- Executive Change: XOMA Royalty's CFO Thomas Burns has resigned to pursue other professional opportunities, indicating a dynamic adjustment within the company's leadership team.
- New CFO Appointment: Jeffrey Trigilio has been appointed as the new CFO, bringing extensive industry experience from his previous role as Chief Financial and Operating Officer at Obsidian Therapeutics.
- Strategic Commitment: Trigilio emphasized the continuation of disciplined capital deployment and innovative deal structuring strategies to enhance the company's royalty portfolio and generate value for shareholders.
- Market Performance: In pre-market trading, XOMA's stock is priced at $29.97, reflecting a 0.40% increase, indicating a positive market reaction to the leadership change.
See More
XOMA Royalty CFO Thomas Burns Steps Down, Jeffrey Trigilio Appointed
- Executive Transition: XOMA Royalty's CFO Thomas Burns has stepped down after nearly 20 years, during which he established a strong financial foundation to support future growth, reflecting the company's stability amid leadership changes.
- New CFO Background: Jeffrey Trigilio has been appointed as the new CFO, bringing extensive experience from various biotech companies and investment banks, which is expected to drive the company's development forward.
- Strategic Direction: Trigilio emphasized the continuation of disciplined capital deployment and innovative deal structuring strategies aimed at enhancing the royalty portfolio and generating shareholder value, indicating the company's confidence in future growth.
- Market Positioning: As a biotechnology royalty aggregator, XOMA Royalty focuses on acquiring potential future economic benefits, assisting biotech firms in achieving their goals of improving human health, showcasing its unique role within the healthcare ecosystem.
See More
XOMA Shares Plunge 22.76% Following Phase 3 Study Failure
- Stock Price Plunge: Following the failure of Rezolute, Inc.'s Phase 3 sunRIZE study to meet its primary endpoint, XOMA's stock price fell by $7.82, or 22.76%, closing at $25.39 on December 19, 2025, indicating strong market concerns about its future prospects.
- Poor Study Results: The study only showed an approximate 45% reduction in hypoglycemia events at the highest dose of 10 mg/kg, which was not statistically significant compared to the placebo group's 40% improvement, reflecting limited drug efficacy that may impact future R&D investments.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether XOMA and its executives engaged in securities fraud or other unlawful business practices, signaling a severe blow to investor confidence in corporate governance and transparency, which could lead to further legal risks.
- Market Reaction Strong: This significant stock price drop not only undermines investor confidence but may also negatively affect XOMA's ability to secure financing and future partnerships, exacerbating market skepticism about its business model.
See More
XOMA Shares Plunge 22.76% Following Phase 3 Study Failure
- Significant Stock Drop: XOMA's stock price fell by $7.82, or 22.76%, to close at $25.39 on December 19, 2025, following Rezolute's announcement that its Phase 3 sunRIZE study did not meet its primary endpoint, directly impacting investor confidence and market performance.
- Poor Study Results: Rezolute reported that while there was an approximate 45% reduction in hypoglycemia events at the highest dose of ersodetug, this was not statistically significant compared to the placebo group's 40% improvement, highlighting the limitations of the drug's efficacy.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether XOMA and its executives engaged in securities fraud or other unlawful business practices, which could further impact the company's reputation and future legal liabilities.
- Increased Investor Vigilance: The study failure and subsequent stock drop have heightened investor scrutiny on XOMA's future developments and market strategies, potentially leading to greater challenges in financing and partnerships for the company.
See More
XOMA Corporation Under Investigation, Stock Plummets 22.76%
- Investigation Launched: Pomerantz LLP is investigating whether XOMA Royalty Corporation has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock declines.
- Poor Clinical Trial Results: The Phase 3 sunRIZE study results released by Rezolute, Inc. indicate that ersodetug failed to meet its primary endpoint in treating congenital hyperinsulinism, raising concerns about XOMA's future prospects in the market.
- Significant Stock Drop: Following the unfavorable news, XOMA's stock price fell by $7.82, or 22.76%, closing at $25.39 per share on December 19, 2025, reflecting investor disappointment in the company's outlook.
- Increased Legal Risks: As the investigation progresses, XOMA may face heightened legal liabilities and potential compensation claims, which could have long-term negative impacts on the company's financial health and market reputation.
See More
XOMA Corporation Under Investigation, Stock Plummets 22.76%
- Investigation Launched: Pomerantz LLP is investigating whether XOMA Royalty Corporation has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further stock volatility.
- Disappointing Clinical Trial Results: Rezolute, Inc.'s Phase 3 sunRIZE study results indicate that ersodetug failed to meet its primary endpoint in treating congenital hyperinsulinism, potentially impacting XOMA's market outlook.
- Significant Stock Drop: Following the adverse news, XOMA's stock price fell by $7.82, or 22.76%, closing at $25.39 on December 19, 2025, reflecting market pessimism regarding the company's future.
- Increased Legal Risks: As the investigation unfolds, XOMA faces potential legal liabilities and compensation risks, which could adversely affect its financial condition and investor trust in the long term.
See More
XOMA Royalty CFO Thomas Burns Resigns, Jeffrey Trigilio Appointed
- Executive Change: XOMA Royalty's CFO Thomas Burns has resigned to pursue other professional opportunities, indicating a dynamic adjustment within the company's leadership team.
- New CFO Appointment: Jeffrey Trigilio has been appointed as the new CFO, bringing extensive industry experience from his previous role as Chief Financial and Operating Officer at Obsidian Therapeutics.
- Strategic Commitment: Trigilio emphasized the continuation of disciplined capital deployment and innovative deal structuring strategies to enhance the company's royalty portfolio and generate value for shareholders.
- Market Performance: In pre-market trading, XOMA's stock is priced at $29.97, reflecting a 0.40% increase, indicating a positive market reaction to the leadership change.
See More
XOMA Royalty CFO Thomas Burns Steps Down, Jeffrey Trigilio Appointed
- Executive Transition: XOMA Royalty's CFO Thomas Burns has stepped down after nearly 20 years, during which he established a strong financial foundation to support future growth, reflecting the company's stability amid leadership changes.
- New CFO Background: Jeffrey Trigilio has been appointed as the new CFO, bringing extensive experience from various biotech companies and investment banks, which is expected to drive the company's development forward.
- Strategic Direction: Trigilio emphasized the continuation of disciplined capital deployment and innovative deal structuring strategies aimed at enhancing the royalty portfolio and generating shareholder value, indicating the company's confidence in future growth.
- Market Positioning: As a biotechnology royalty aggregator, XOMA Royalty focuses on acquiring potential future economic benefits, assisting biotech firms in achieving their goals of improving human health, showcasing its unique role within the healthcare ecosystem.
See More
XOMA Shares Plunge 22.76% Following Phase 3 Study Failure
- Stock Price Plunge: Following the failure of Rezolute, Inc.'s Phase 3 sunRIZE study to meet its primary endpoint, XOMA's stock price fell by $7.82, or 22.76%, closing at $25.39 on December 19, 2025, indicating strong market concerns about its future prospects.
- Poor Study Results: The study only showed an approximate 45% reduction in hypoglycemia events at the highest dose of 10 mg/kg, which was not statistically significant compared to the placebo group's 40% improvement, reflecting limited drug efficacy that may impact future R&D investments.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether XOMA and its executives engaged in securities fraud or other unlawful business practices, signaling a severe blow to investor confidence in corporate governance and transparency, which could lead to further legal risks.
- Market Reaction Strong: This significant stock price drop not only undermines investor confidence but may also negatively affect XOMA's ability to secure financing and future partnerships, exacerbating market skepticism about its business model.
See More
XOMA Shares Plunge 22.76% Following Phase 3 Study Failure
- Significant Stock Drop: XOMA's stock price fell by $7.82, or 22.76%, to close at $25.39 on December 19, 2025, following Rezolute's announcement that its Phase 3 sunRIZE study did not meet its primary endpoint, directly impacting investor confidence and market performance.
- Poor Study Results: Rezolute reported that while there was an approximate 45% reduction in hypoglycemia events at the highest dose of ersodetug, this was not statistically significant compared to the placebo group's 40% improvement, highlighting the limitations of the drug's efficacy.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether XOMA and its executives engaged in securities fraud or other unlawful business practices, which could further impact the company's reputation and future legal liabilities.
- Increased Investor Vigilance: The study failure and subsequent stock drop have heightened investor scrutiny on XOMA's future developments and market strategies, potentially leading to greater challenges in financing and partnerships for the company.
See More
